VJVirtual | Galinpepimut-S: mechanism of action and use in AML, ovarian cancer & mesothelioma

Wilms’ tumor gene (WT1) encodes a transcription factor that plays an important role in cell growth and differentiation, and is highly expressed in leukemia and various solid tumors. In this interview, Angelos M. Stergiou, MD, ScD, SELLAS Life Sciences Group, New York, NY, provides an overview of Wilms tumor 1 (WT1), as well as galinpepimut-S, a WT1-targeting immunotherapy that is comprised of four peptide chains that induce a strong innate immune response (CD4+/CD8+) against the WT1 antigen and across a broad range of HLA types. Dr Stergiou discusses current investigations evaluating GPS in patients with acute myeloid leukemia (AML), as well as ovarian cancer and mesothelioma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).